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ABSTRACT 
Objective Sleep is often disturbed in patients with advanced cancer. There is limited knowledge about sleep in 
cancer patients treated with strong opioids. This study  examines sleep quality in patients with advanced cancer 
who are treated with a WHO step III opioid for pain.  
Methods An international, multi-centre, cross-sectional study with 604 adult cancer pain patients using WHO 
step III opioids at nine hospitals in five European countries. Self-reported sleep were assessed by the Pittsburgh 
Sleep Quality Index (PSQI) global score (range; 0–21; score >5 indicate poor sleep). PSQI includes sleep 
quality, sleep latency, sleep duration, sleep efficiency, sleep disturbances, use of sleep medications and daytime 
dysfunction. Pain and quality of life were assessed by the Brief Pain Inventory and EORTC QoL questionnaire. 
Results The median age was 62 years, 42% were female, mean Karnofsky performance score (KPS) was 62.5 
(±14.2) and mean oral daily morphine equivalent dose was 303 mg/24h (±543.8 mg). The mean PSQI global 
score was 8.8 (±4.2) (range 0-20). Seventy-eight percent were poor sleepers. All parts of PSQI were affected and 
44% reported trouble sleeping caused by pain. Predictors of PSQI global scores were pain intensity, emotional 
function, constipation, financial difficulties and KPS (Adjusted R-Square = 0.21).  
Conclusion The majority (78%) of advanced cancer patients treated with opioids experienced poor sleep quality. 
Pain intensity, emotional function, constipation, financial difficulties, and KPS predicted PSQI global scores. 
The clinical implication is that physicians should assess and if possible treat sleep disturbance in patients with 
advanced cancer disease.  
 
 
 
 
 
 
 
  
  
INTRODUCTION 
Cancer patients experience several disease- and treatment-related symptoms. Based on a study of 3000 
ambulatory cancer patients, Cleeland et al. observed that disturbed sleep was one of the three most frequent 
symptoms.1 The prevalence of sleep disturbance  in cancer patients varies from 25 to 59 percent,2 which is higher 
than the typical rate of 15-25% observed in the general population.3  
Most studies of sleep disturbance in cancer include patients undergoing curative therapy or are conducted in 
cancer survivors.4 However, sleep is recognized as a frequent concern in small samples of patients with 
advanced cancer with a pooled prevalence (35%) similar to shortness of breath (35%), depression (39%), and 
worrying (36%).5 A Greek study including 82 patients with advanced cancer found that most patients (96%) 
were classified as poor sleepers by using a self-report assessment of sleep.6 A prospective, observational UK 
study found that 47% of the advanced cancer patients (n=60) did not sleep well.7 Furthermore, both an Italian 
and a US study observed that about 60% of palliative care patients had significant sleep disturbances.8, 9  
Results from sleep studies of sleep in early stage of cancer may not be representative for patients with advanced 
cancer and short life expectancy. Sleep in advanced cancer patients may be more influenced by symptoms such 
as pain, fatigue and depression, symptoms for which higher intensity is associated with a higher risk of sleep 
disturbance.10 As an example, Hugel et al. found that 60% of the patients with advanced cancer reported that 
uncontrolled symptoms caused disturbed sleep,11 and Delgado-Guau et al. found that sleep disturbance was 
associated with increased frequency of pain, depression, anxiety, and a poorer well-being.12 In semi-structured 
interviews with cancer patients using opioids, disturbed sleep was repeatedly reported as a bothersome 
consequence of having pain.13 
Patients with advanced cancer use a high number of drugs, including opioids for moderate to severe pain.14  
Common side effects of long-term opioid use are constipation, nausea, and sedation.15 Opioid therapy is also 
known to affect sleep in different ways. A clinical review from 2007 found that sleep architecture is at risk to be 
abnormal in patients who use opioids with reduced rapid eye movements (REM) sleep, increased wakefulness, 
and increased arousals from sleep, reduced total sleep time and sleep efficiency.16 Moreover, opioids influence 
sleep processes, such as nocturnal apnea and O2 desaturation.17, 18  In patients with advanced cancer, it has been 
shown that the use of a World Health Organization (WHO) step III opioid was more related to poor quality of 
sleep than the use of the step II opioid codeine.19 However, despite this findings, and the general knowledge 
about a possible effect from opioids on sleep, the relationship between opioid use and sleep is not established for 
cancer pain patients. .   
As described above, recent studies on sleep quality in advanced cancer have found an association between sleep 
disturbance and cancer related symptoms. However, most of the studies combined patients using opioids and 
patients not using opioids in the analyses.8, 20-22 Other studies have cohorts of patients treated with both WHO 
step II and step III opioids,6, 23 and some studies do not report the use of opioids.7, 9, 11, 12, 24-26 Hence, the literature 
on sleep quality in advanced cancer consists of heterogeneous groups of patients, and the research  investigating 
pain-related sleep disturbances in patients with advanced cancer using a WHO step III opioid is sparse. Given 
the potential effects from opioids on sleep and the widespread use of opioids in patients with advanced cancer, it 
is clinical relevant to assess sleep in this group of patients.  
  
Therefore, the aim of the present study was to investigate sleep quality in patients with advanced cancer treated 
with a WHO step III opioid for cancer pain by addressing the following research questions: i: “What is the 
prevalence of sleep disturbance in a large international sample of cancer patients on a WHO step III opioid?” ii: 
“To what extent do pain intensity and other prevalent symptoms correlate with sleep quality in this cohort? iii: 
“To what extent do pain intensity and other cancer related variables predict sleep quality in this cohort?”  
METHODS  
This study is a sub study of the European Pharmacogenetic Opioid Study (EPOS), an international multicentre, 
cross-sectional study.14 Within the EPOS study, nine hospitals in Denmark, Germany, Lithuania, Norway and 
Switzerland, recruited patients for self-reports of sleep quality. Adult patients (>18 years) with a malignant 
disease and a  treatment with a step III opioid on the WHO analgesic ladder were included.27 Patients not 
consenting to participate in the study or not competent in the language used at the study centre were excluded 
from the study. The study was approved by ethical committees at each study centre and performed according to 
the rules of the Declaration of Helsinki. Written informed consent was obtained from all patients before 
inclusion.  
Patient reported outcome measures 
Sleep quality was reported by the modified Pittsburgh Sleep Quality Index (PSQI).28 The PSQI assesses sleep 
quality during the previous month and consists of 19 self-rated questions. The 19 items are grouped into seven 
component scores, weighted equally on a 0-3 scale. The components are subjective sleep quality, sleep latency, 
sleep duration, habitual sleep efficiency, sleep disturbances, use of sleep medications and daytime dysfunction.28 
The seven component scores are summed to yield a PSQI global score denoting sleep quality, with a range of 0-
21; higher scores indicate worse sleep quality. PSQI global scores > 5 indicate poor sleep.12, 28  
Patients scored their pain intensity on the Brief Pain Inventory (BPI).29 BPI items were average pain, worst pain 
and pain interference with sleep the past 24 hours, all scored at a 0-10 numerical rating scale (NRS). Quality of 
life was patient reported by European Organisation for Research and Treatment of Cancer Quality of Life 
Questionnaire Core30 (QLQ-C30, version 3.0).30 The QLQ-C30 incorporates nine multi-item scales: five 
functional scales (physical, role, cognitive, emotional, and social); three symptom scales (fatigue, pain, and 
nausea and vomiting); and a global health/quality-of-life (QoL) scale consisting of two items. Six single item 
scales assess symptoms (dyspnoea, appetite loss, sleep disturbance, constipation and diarrhoea) and the 
perceived financial impact of having a cancer disease.  
Health care personnel reported measures  
The following demographic and clinical variables were obtained by health care personnel: age, gender, weight, 
height, concomitant diseases, previous known history of alcoholism or drug abuse, department category (i.e. 
inpatient and out-patients clinic), haemoglobin serum concentrations, cancer diagnosis and metastases, and time 
interval since the cancer disease was diagnosed. All medications and dosages including opioids for the foregoing 
24 hours, duration of opioid treatment, and use of rescue opioids in last 24h and route of opioid administration 
were registered. Oral daily morphine equivalent dose was calculated.14 Performance status was rated using the 
  
Karnofsky performance status (KPS) which ranges from 0 (i.e., dead) to 100 (i.e., normal activity) scale.31 
Cognitive function was assessed by the Mini Mental State Exam (MMSE).32  
Statistical analysis 
Means, standard deviations and range were reported for all scale variables. Sleep characteristics were given as 
mean values of the seven component scores and for the PSQI global scores from the PSQI. Univariate 
association between PSQI global scores and pain average and worst pain intensity, quality of life outcomes, oral 
daily morphine equivalent opioid dose and number of days on opioids were reported by Spearman`s rank 
correlation coefficients (rs).   
To examine predictive factors of PSQI global scores a multiple regression model was constructed. PSQI global 
score (0-21) was used as the outcome variable. Bivariate linear regression was used to select symptoms and 
characteristics as potential predictors in the linear multivariate analyses of PSQI global scores. The significance 
level to include a variable in the multivariate analyses was p <0.10. Variables that were included in the model 
were: pain intensity from the BPI and global health QoL, physical function, emotional function, and the 
symptom scales fatigue, dyspnoea, constipation and financial difficulties from the QLQ-C30. In addition, oral 
daily morphine equivalent dose, days on opioids and KPS were included in the backward elimination analyses. A 
p-value ˂ 0.01 was applied for removing variables.  
Data were analysed by IBM SPSS Statistics version 20.0 for Windows (IBM Corporation, Armonk, USA).   
RESULTS 
A total of 931 patients from nine hospitals located in five countries were recruited from February 2004 to April 
2008 (Denmark n= 30, Germany n= 452, Lithuania n= 54, Norway n= 331 and Switzerland n= 64). Of the 
patients, 327 patients did not complete the PSQI (too sick n= 153, did not want to n= 91 and unknown reason n= 
83). A total of 604 patients were included in the analyses.   
Sample characteristics 
Demographics and clinical characteristics are shown in table 1. Of the 604 patients, 42% were female. The 
median age was 62 years. Mean KPS was 62.5 (±14.2). Twelve percent of the patients had a KPS of 50 or lower, 
corresponding to an ECOG Performance status III-IV. The mean opioid dose, expressed as the oral daily 
morphine equivalent dose, was 303 mg/24 h (±543.8 mg). The four main cancer diagnoses in the cohort were 
gastro- (23.1%), lung- (18.7%), prostate- (15.2%) and breast cancer (10.8%). The majority (84.1%) had one or 
more metastases.  The mean MMSE score was 27.3 (±3.2) (12-30). 
 
 
 
Table 1 Demographic and cancer related patient characteristics (n=604) 
  
  
Characteristics 
 
N  (Percent)1,2 
Female, Gender 253  (42) 
Karnofsky Performance status score3, mean (SD) (min-max)  62.5  (14.2) (20-100) 
Age, years, median, (min-max)   62  (20-91)   
Body mass index, mean, (SD) (min-max)   23.5  (4.6 ) (13.8-43.2) 
Treatment setting; inpatient/outpatient  460 (76.2)/144 (23.8) 
Cancer diagnosis:  
     Gastro intestinal/liver/pancreas   140  (23.2) 
     Lung cancer/mesothelioma 113  (18.7) 
     Prostate cancer 92  (15.2) 
     Breast cancer 65  (10.8) 
     Urological cancer 51  (8.4) 
     Head and neck cancer 39  (6.5) 
     Female reproductive organs 25  (4.1) 
     Haematological cancer 25  (4.1) 
     Skin cancer 17  (2.8) 
     Sarcoma 15  (2.5) 
     Unknown origin 14  (2.3) 
     Other cancer 8  (1.3) 
Time since cancer diagnosis, median days (min-max)   15.00 (0-286) 
Metastasis, present 508  (84.1) 
     Bone 287  (47.5) 
     Liver 152  (25.2) 
     Lung 124  (20.5) 
     CNS 28  (4.6) 
Oral daily morphine equivalent dose, mean, mg (SD) (min-max)   303 (543.8) (10-8064) 
Number of days on opioids, mean (SD) (min-max) 186 (345.3) (3-2418) 
Previous known abuse of alcohol or drugs 44 (7.3) 
Haemoglobin serum concentrations4 mean (SD) (min-max) 11.4 (1.6) (7.3-16.1) 
Use of medication that may influence sleep:  
    Steroids 
    Antidepressants 
    Benzodiazepines 
    Hypnotics 
 
239 (39.6) 
130 (21.5) 
106 (17.5) 
74  (12.3) 
Co-morbidities  
     Heart disease 145  (24.0) 
     Vascular disease 92  (15.2) 
      Lung disease 60  (9.9) 
     Neurological disease 25  (4.1) 
     Psychiatric disease 21  (3.5) 
1 Unless otherwise specified, 2 Missing values were ˂3% for all variables, expect for “Body mass index” (5.8 % 
missing), “Number of days on opioids” (7.8 % missing) and “Time since cancer diagnosis” (9.7 % missing), 
3Karnofsky performance status using a 0 (i.e., dead) to 100 (i.e., normal activity) scale,31  4 g/dl 
Sleep quality and cancer related characteristics 
The majority of the patients (78%) were categorized as having poor sleep quality (PSQI global scores >5). The 
mean PSQI global score was 8.8 (±4.2) (range 0-20). The distribution of global PSQI scores is given in fig.1. 
Descriptive statistics of sleep quality on the seven components scores of the PSQI are shown in table 2. The 
component from the PSQI that was most affected was “sleep disturbance” with a mean score of 1.6 (±0.7) (0-3). 
Forty-four percent of the patients reported having trouble sleeping because of pain three or more times a week, 
57% reported trouble sleeping because of having to use the bathroom during the night for three or more times a 
week and 27% had trouble sleeping because of waking up in the middle of the night or early morning for three or 
more times a week. One-third of patients reported trouble sleeping because of difficulty initiating sleep for three 
or more times a week.  
  
Table 2 Descriptive statistics of sleep quality and cancer related symptoms 
 
 
 
 
Mean 
 
SD 
 
Min 
 
Max 
 
Missing (%) 
Sleep1      
   PSQI global score 8.8 4.2 0 20 11.0 
   Subjective sleep quality 1.4 0.8 0 3 2.6 
   Sleep latency 1.3 1.0 0 3 7.3 
   Sleep duration 0.7 1.0 0 3 5.1 
   Habitual sleep efficiency 1.3 1.2 0 3 10.4 
   Sleep disturbance 1.6 0.7 0 3 8.8 
   Use of  sleep medication 1.3 1.4 0 3 3.5 
   Daytime dysfunction 1.5 0.1 0 3 5.3 
Pain2      
   Average pain  3.6 2.2 0 10 5.0 
   Worst pain  5.1 2.7 0 10 2.2 
Health related QoL3      
   Global health QoL3a 35.8 21.5 0 91.67 3.3 
   Physical function3a 37.0 24.6 0 100 1.5 
   Emotional function3a 54.6 27.5 0 100 1.5 
   Fatigue3b 70.6 22.9 0 100 1.7 
   Nausea and vomiting3b 29.4 30.7 0 100 1.3 
   Dyspnoea3b 38.1 36.2 0 100 2.2 
   Diarrhoea3b 16.5 28.0 0 100 2.8 
   Constipation3b 49.8 38.4 0 100 1.7 
   Financial difficulties3b 31.5 37.1 0 100 3.5 
1 Sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI)28 
2 Pain intensity assessed by the Brief Pain Inventory, numerical rating scale 0-1029  
3 Health related quality of life assessed by the European Organisation for Research and Treatment of Cancer 
Quality of Life Questionnaire (QLQ-C30). 30 
3a QLQ-C30 functioning scale (0-100). A high score on the functional scales/Global QoL scale means a good 
function/quality of life. 3bQLQ-C30 symptom scale (0-100). A high score on symptom scales denotes higher 
symptom burden. 
 
Twenty-five percent of the patients reported that pain severely interfered with sleep (NRS 7-10). Corresponding 
numbers for pain to moderately interfere (NRS 4-6) or to mildly interfere (NRS 1-3) with sleep were 24% and 
26%, respectively. A quarter of the patients reported that pain did not interfere with sleep (NRS 0).  
The mean value of average pain assessed by the BPI was 3.6 (±2.2) (0-10). The mean value of the global health 
QoL scale was 35.8 (±21.5) (0-91.7). The fatigue scale of the QLQ-C30 received the highest mean score 70.6 
(±22.9) (0-100) (table 2).  
Correlations between sleep quality and cancer related symptoms 
The correlations between PSQI global scores and pain intensity, dimensions of quality of life, cognitive status 
and oral daily morphine equivalent dose are shown in table 3. PSQI global scores were correlated with average 
pain intensity and worst pain intensity (Spearman`s Rho (rs)=0.201 and 0.164; P˂0.001, respectively). 
Statistically significant negative correlations were seen between PSQI global scores and global health QoL (rs= -
0.131; p=0.003), physical function (rs=-0.149; p=0.001) and emotional function (rs=-0.344; P˂0.001). 
Statistically significant correlations were observed between PSQI global scores and the symptom scales 
dyspnoea and constipation (rs=0.148; p=0.001, rs=0.212; P˂0.001, respectively). Fatigue and financial 
  
difficulties from the QLQ-C30 correlated both to PSQI global scores (rs=0.244 and 0.270; P˂0.001, 
respectively). There was a correlation between PSQI global scores and oral daily morphine equivalent dose 
(rs=0.137; P=0.002). KPS was negatively correlated with PSQI global scores (rs=-0.168; P˂0.001).  
Table 3 Correlations between sleep quality and pain intensity and other cancer related variables 
 
 
 
 
PSQI global score1  
 
 
Spearman’s   
Rho 
          P-value 
Pain intensity, average pain2  0.201 ˂0.001 
Pain intensity, worst pain2 0.164 ˂0.001 
Global health QoL 3a  - 0.131 0.003 
Physical function3a  - 0.149 0.001 
Emotional function3a  - 0.344 ˂0.001 
Fatigue3b  0.244 ˂0.001 
Nausea and vomiting3b  0.079 0.067 
Dyspnea3b  0.148 0.001 
Diarrhea3b  0.018 0.680 
Constipation3b 0.212 ˂0.001 
Financial difficulties3b 0.270 ˂0.001 
Cognitive status4  0.005 0.911 
Oral daily morphine equivalent dose5 0.137 0.002 
Days on opioids6 - 0.029 0.521 
Karnofsky performance status7 - 0.168 ˂0.001 
1 Sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI) global score (0-21)28 
2 Pain intensity assessed by the Brief Pain Inventory, numerical rating scale 0-1029  
3 Health related quality of life assessed by the European Organisation for Research and Treatment of Cancer   
Quality of Life Core Questionnaire (QLQ-C30).30  
3a QLQ-C30 functioning scale (0-100). A high score on functional scales means a good function/quality of life, 3b 
QLQ-C30 symptom scale (0-100). A high score on symptom scales means severe symptoms and hence a poor 
quality of life.  
4 Assessed by the Mini Mental State Exam (MMSE)32  
5 Oral daily morphine equivalent dose  (mg/24 h ) 
6 Number of days on opioid treatment before inclusion day in the present study 
7 Performance status was rated using the Karnofsky performance status using a 0 (i.e., dead) to 100 (i.e., normal 
activity) scale31 
Predictors for sleep quality  
The bivariate analyses identified pain intensity, global health QoL, physical and emotional function, fatigue, 
dyspnoea, constipation, financial difficulties, oral daily morphine equivalent dose and KPS as potential 
predictors in the multivariate analyses of PSQI global scores (0-21) (Table 4). The significant predictors of PSQI 
global scores in the multivariate analysis were pain intensity, emotional function, constipation, financial 
difficulties and KPS. The regression model explained 21% of the total variance (Table 4).   
  
 
Table 4 Bivariate and multiple linear regression models of associating factors and predictors of sleep quality (PSQI global score1). Unstandardized regression coefficients (B), 
Standard Error (SE) and 95 % Confidence Intervals (95% CI) 
 Bivariate linear regression model Multiple linear regression model, backward method 
 
Independent variables B 
 
SE 95& CI  P B SE 95& CI  P 
Constant       10.273 0.959  8.389 to 12.158 ˂0.001 
Pain intensity2  0.391 0.082  0.230 to  0.552  ˂0.001 0.191 0.079  0.035 to 0.347 0.016 
Global health QoLe3a -0.025 0.008 -0.042 to -0.008 0.003     
Physical function3a -0.027 0 007 -0.041 to -0.012 ˂0.001     
Emotional function3a -0.052 0.006 -0.064 to -0.040 ˂0.001 -0.037 0.007 -0.050 to -0.023 ˂0.001 
Fatigue3b  0.043 0.008  0.028 to  0.058 ˂0.001     
Nausea and vomiting3b  0.008 0.006 -0.004 to  0.020 0.186     
Dyspnea3b   0.017 0.005  0.007 to  0.027 0.001     
Diarrhea3b  0.004 0.007 -0.009 to  0.017 0.562     
Constipation3b  0.023 0.005  0.014 to  0.032 ˂0.001 0.017 0.004  0.009 to 0.026 ˂0.001 
Financial difficulties3b  0.031 0.005  0.022 to  0.040 ˂0.001 0.020 0.005  0.010 to 0.030 ˂0.001 
Cognitive function4 -0.038 0.060 -0.155 to  0.079 0.525     
Oral daily morphine equivalent dose5  0.001 0.000  0.000 to  0.002 0.013     
Days on opioid6  0.000 0.001 -0.001 to  0.001 0.419     
Karnofsky performance status7 -0.049 0.013 -0.074 to -0.025 ˂0.001 -0.026 0.012 -0.050 to -0.002 0.034 
Adjusted R Square  0.211 
1 Sleep quality assessed by the Pittsburgh Sleep Quality Index (PSQI) global score (0-21)28 
2 Pain intensity assessed by the Brief Pain Inventory by pain on the average on a numerical rating scale 0-1029 
3 Health related QoL assessed by the European Organisation for Research and Treatment of Cancer  Quality of Life Core Questionnaire (QLQ-C30)30  
3a QLQ-C30 functioning scale (0-100) a high score on functional scales means a good function/quality of life 
3b  QLQ-C30 symptom scale (0-100). A high score on symptom scales means severe symptoms and hence a poor quality of life. 
4 Assessed by the Mini Mental State Exam (MMSE)32  
5 Oral daily morphine equivalent dose (mg/24 h)  
6 Number of days on opioid treatment before inclusion day in the present study 
7 Karnofsky performance status using a 0 (i.e., dead) to 100 (i.e., normal activity) scale31 
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DISCUSSION 
Interpretation of main findings 
In this large, international multi-centre study we found that the majority (78%) of the 604 patients with advanced 
cancer treated with a WHO step III opioid for cancer pain had poor sleep quality as measured by the PSQI. PSQI 
global scores were statistically significantly correlated with worse outcomes in pain intensity, physical function, 
emotional function, fatigue, dyspnoea, constipation, financial difficulties, KPS and higher oral daily morphine 
equivalent doses. However, the magnitude of the correlations was moderate (range from -0.35 to 0.15). Pain 
intensity, emotional function, constipation, financial difficulties and KPS were found to be significant predictors 
of poor sleep quality in the multivariate regression analysis.  
Previous studies have generally demonstrated prevalence of sleep disturbances ranging from 23 to 96 percent in 
patients with advanced cancer disease.6, 8, 12, 23-25, 33 These results are obtained from various cancer populations 
such as out-patients,33 patients with a specific cancer diagnosis,25 and unselected palliative care patients.8 The 
studies have also used various instruments to report sleep disturbances such as Athens Insomnia Scale,8 the 
Insomnia Severity Index,24 and PSQI.9, 33 The significance of the choice between instruments is demonstrated by 
Yennurajalingam et al. who observed that a NRS sleep score did not reflect the variability in PSQI scores.12  
Sleep disturbance can be related to both pain and the use of opioids.11-13, 17 In the present study most patients 
reported that pain interfered with sleep and statistically pain intensity was a significant predictor of sleep quality 
measured by PSQI. The inverse relation between PSQI sleep quality measures and pain is in line with results 
from previous studies (ref). The consistence of these data and the common experience that most of us have with 
the effect of pain on sleep indicate that sleep disturbances not only co-exist with pain. Opioids may improve 
sleep by its pain relieving effects and due to sedation. However, opioids may also interact with central nervous 
mechanisms influencing sleep rhythms.18, 34 Also a relationship between the use of opioids and sleep may change 
due to development of tolerance of opioids effects.17 Previous studies have either not reported the use of opioids 
or assessed the use of opioids as a binary yes/no variable. In this study, including a selected cohort with all using 
a WHO step III opioid, we observed a high prevalence of sleep disturbance. The daily dose and duration of 
opioid therapy did not contribute statistically significant to the explained variation in sleep quality measured by 
PSQI (sleep score). However, the inverse relation between sleep quality (measured by PSQI) and pain in the 
present study is consistent with the results from previous studies.9, 12, 19, 24   
Emotional function, financial difficulties and constipation were significant predictors of sleep quality in the 
multivariate regression analysis in this study. Emotional function in the QLQ-C30 encompasses four items:  
feeling tense, being worried, being irritable and feeling depressed. Patients with lower scores on emotional 
function reported more sleep disturbance. This result is consistent with previous research where sleep 
disturbance is associated with increased frequency of depression and a worse sense of well-being.6, 12 Secondly, 
financial difficulties were a significant predictor of poor sleep in this study. Self-reported “financial burden” or 
“financial stress” is common among cancer patients,35 but calls for further investigation as there may be some 
overlap or interaction between emotional function/worries and financial difficulties as assessed by the QLC-C30.  
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Thirdly, constipation was one of the symptom scales from the QLQ-C30 questionnaire that was observed as a 
predictor of poor sleep quality in the present study. Opioids are associated with significant gastrointestinal 
adverse effects that impair patients quality of life,36 and constipation is common in palliative care patients.37 
Gastrointestinal discomfort may well disturb sleep quality. However, because of the cross sectional design of the 
present study, we cannot determine if constipation caused poor sleep quality or simply this is an association 
caused by a shared determinant, advanced disease and opioids. However, constipation is a medical problem and 
optimized treatment; if possible, unlikely would reduce sleep quality in this group.  
In addition to cancer related symptoms, the multivariate regression analyses showed that the patient’s 
performance status was a significant predictor of PSQI global score. Karnofsky performance status reflects the 
patient`s ability to carry on normal activities, or the patient`s degree on dependence on help and nursing care.31 
Poor functional performance was associated with poor sleep. This result is consistent with a recently published 
Italian study were sleep in advanced cancer measured by the Athens insomnia scale, was significantly associated 
with lower KPS levels.38  
Sleep quality consists of several aspects of sleep, such as sleep duration, sleep latency or number of arousals.28 
This is reflected by the PSQI, which measures seven different aspects of sleep quality. We found that in this 
cohort of patients with advanced cancer who were treated with a WHO step III opioid, all seven components of 
sleep quality were affected (Table 2). This means that sleep disturbance in cancer pain patients is a complex mix 
of difficulty initiating sleep, difficulties to stay asleep, early wakening and various external factors disturbing 
sleep such as having to use the bathroom, cannot breathe comfortably, feeling to cold or hot, or having pain.  
Strengths and Limitations 
Strengths of this study are the relatively large number of patients that were recruited from hospitals in several 
countries, the prospective design and the use of an instrument developed specifically for assessment of sleep 
quality. Moreover it includes palliative care patients only, for whom findings are clinically relevant. Limitations 
include the cross-sectional design. In this cohort of patients with advanced cancer, the nature of the relationship 
between pain and sleep quality is considered to be quite complex and it might be that the relationship is 
reciprocal.39 Because of the cross-sectional design, we cannot draw any conclusion regarding the direction of the 
relationship between pain and sleep quality. Another limitation is that factors included in the multivariate 
regression model explained only 21% of the variability of the sleep quality. Thus, other hereto-unknown factors 
are important for sleep quality. It would have been of interest to examine the difference in sleep quality in 
patients with and without opioid treatment. However, groups of cancer patients using no opioids versus those in 
need of opioid therapy will usually? be at different stages of their cancer disease and difficult to compare. 
Finally, the data reported in this study was obtained almost a decade ago and changes in palliative care may have 
altered incidences of sleep disturbances. However, recent data show that the prevalence of sleep disturbances in 
cancer is still high,8, 9, 12 thereby arguing it is still important to address this symptom.  
Clinical implications  
Knowledge of symptom prevalence is important for clinical practice.5 The extent of high prevalence of sleep 
disturbance and the impact on sleep quality of cancer related variables such as pain intensity, emotional function, 
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constipation, financial difficulties and KPS, highlights the clinical relevance of this problem in patients with 
advanced cancer treated with a WHO step III opioid for cancer pain. All dimensions of sleep quality were 
affected, which suggest that sleep disturbances in cancer pain patients encompass several clinical challenges. As 
for other symptoms it is important to categorize and classify various sleep disturbances in order to address each 
patient’s individual needs. In this study, sleep quality measured by PSQI is statistically related to other medical 
problems that could be assessed and treated per se and maybe have beneficial effect on sleep: pain intensity, 
emotional function, fatigue and constipation. 
Only 12% of the patients in this cohort used hypnotics. Nevertheless, the majority of the patients (78%) reported 
poor sleep quality. This might illustrate that sleep disturbance is undertreated or that the use of hypnotics is not 
the best treatment of sleep disturbance in this cohort. Moreover, patients with advanced cancer rarely present 
with a single symptom. Hence, there is a need for a comprehensive assessment of symptom burden in which 
sleep quality is one of many. 
Conclusions  
This study found that the majority (78%) of the patients with advanced cancer treated with a WHO step III 
opioid for cancer pain reported poor sleep quality as measured by the PSQI. Significant predictors of poor sleep 
quality were pain intensity, emotional function, constipation, financial difficulties and Karnofsky performance 
status. Considering the high prevalence of poor sleep quality, health care personnel should routinely assess sleep 
problems by using patient reported outcome measures. More research is needed in order to examine the effects 
on sleep quality from using opioids. The high level of sleep disturbance in patients with advanced cancer treated 
with a step WHO III opioid for cancer pain calls for special attention given to this group of patients.  
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